Clostridium Difficile Diagnostics and Treatment Market to Exceed the US$ 2,576.3 Million Threshold by 2025 | CAGR: 8.2%: Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

The global clostridium difficile diagnostics and treatment market was pegged at US$ 1,272.2 million in 2016 and is projected to exhibit a CAGR of 8.2% over the forecast period (2017-2025). 

Get FREE Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-pdf/1499

A higher rate antibiotic consumption leading to impaired natural flora, creates a conducive environment for growth of C.difficile bacterium, which is a major growth driver for the global clostridium difficile diagnostics and treatment market. Pivotal factors such as presence of sensitive and easily accessible diagnostic tests, and availability of generic antibiotics (metronidazole, and Vancomycin), and is expected to fuel the global market growth in the near future.

According to the Center for Disease Control & Prevention (CDC), the burgeoning prevalence of clostridium difficile infection is increasing, and it is the most common healthcare-associated infection. In order to cater to increasing demand for drugs, generic manufacturers have capitalized on patent losses of standard antibiotics for the treatment of clostridium difficile infection such as metronidazole and vancomycin. Lupin Ltd., Sandoz, Inc., Mylan Laboratories Ltd., and others offer generic version of these antibiotics. Furthermore, manufacturers are developing novel therapies such as monoclonal antibodies for the treatment of this disease. For instance, CutisPharma launched FIRVANQ (vancomycin hydrochloride), an oral solution, in April 2018. Increasing research and development of alternative therapies such as microbiome therapeutics and vaccines is expected to positively impact growth of the clostridium difficile treatment market in the upcoming years.

Browse Press Release: https://bit.ly/34o2sYh

Several diagnostics manufacturers across the globe are focusing on offering sensitive diagnostic tests for rapid diagnosis of clostridium difficile infection. For instance, HiberGene Diagnostics received CE mark for HG C. difficile test in 2016 and DiaSorin Molecular launched clostridium difficile molecular test in 2016. GenePOC, Inc. received the U.S. Food & Drug Administration approval for its GenePOC Cdiff molecular test in the U.S. in 2017. Furthermore, bioMérieux launched Vidas C. difficile toxin A&B, the first automated detection test for clostridium difficile A and B toxins, in 2017.

A number of organizations are working towards propagating the global awareness about clostridium difficile infection.  CutisPharma and C Diff Foundation announced plans to enter into partnership to increase clostridium difficile awareness among populace, in 2017. Furthermroe, in March 2018, C Diff Foundation awarded its “Making a Difference” award to CutisPharma, Inc., for its contribution in increasing awareness regarding clostridium difficile awareness.

Apply Promo Code “STAYHOME” And Get an Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/1499

Key Takeaways:

• Manufacturers are developing alternative therapies such as vaccines and microbiome therapeutics, which is expected to aid in market growth over the projected timeframe.
• Accurate diagnostic tests, such as polymerase chain reaction-based assays, and point-of-care diagnostics for C. difficile are gaining significant traction around the world.
• The Asia Pacific market is expected to witness significant growth, owing to presence of generic players such as Cipla and Lupin that offer generics for C. difficile.
• The most prominent players operating in the global clostridium difficile diagnostics and treatment market include Roche AG, Thermo Fisher Scientific Inc., Merck & Co., Pfizer, Inc., Actelion Pharmaceuticals, Abbott Laboratories, Trinity Biotech, Summit Therapeutics, Baxter International Inc., Sanofi S.A., Novartis AG, and AstraZeneca Plc.

Special Requirements?
We value your investment and offer customization as per your requirements.

Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/1499

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.